Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study

Thymic carcinoma (TC) is a rare cancer with a poor prognosis and limited treatment options, especially after relapse. In this open-label, two-stage, multicentre, single-arm and phase II trial, the main eligibility criteria were unresectable or recurrent TC, an Eastern Cooperative Oncology Group–perf...

Ausführliche Beschreibung